References
Siew C Ng, Hai Yun Shi, Nima Hamdi et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies // www.thelancet.com Published online October 16, 2017
http://dx.doi.org/10.1016/S0140-6736(17)32448-0
Nguyen G, Chong C, Chong R. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States //Journal of Crohn’s and Colitis (2014) 8: 288-295
Dahlhamer J, Zammitti E, Ward B, Wheaton A, Croft J. Prevalence of inflammatory bowel disease among adults aged ≥18 years—United States, 2015. MMWR Morb Mortal Wkly Rep. (2016) 65(42): 1166–1169.
https://www.cdc.gov/mmwr/volumes/65/wr/mm6542a3.htm
Xu F, Wheaton A, Liu Y, Lu H, Greenlund K. Hospitalizations for Inflammatory Bowel Disease Among Medicare Fee-for-Service Beneficiaries — United States, 1999–2017. MMWR Morb Mortal Wkly Rep (2019) 68: 1134–1138. DOI:
http://dx.doi.org/10.15585/mmwr.mm6849a2
Park K, Ehrlich O, Allen J at al. The cost of inflammatory bowel disease: an initiative from the Crohn’s and Colitis foundation //Inflamm Bowel Dis (2020) 26 (1)
Peters L, Perrigoue J, Mortha A. et al. A functional genomics predictive network model identifies regulators of inflammatory bowel disease // Nature Genetics (2017), 49 (10): 1437-1449
Gradel K, Nielsen H, Schnheyder H. et al. Increased short- and long-term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis // Gastroenterology (2009), 137 (2): 495-501
Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease // Journal of Immunology research (2019), article ID 7247238,
https://doi.org/10.1155/2019/7247238
Suhal Mahid, Kyle Minor, Roberto Solo et al., Smoking and inflammatory bowel disease: a meta-analysis // Mayo Clin Proc (2006), 81(11):1462-71. doi: 10.4065/81.11.1462
Ananthakrishnan A, Khalili H, Konijeti G, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis // Gastroenterology (2013), 145(5): 970-977
World Gastroenterology Organisation Global Guideline. Inflammatory bowel disease: a global perspective // Clin Gastroenterol (2016), 50 (10): 803-818
Ott C, Scholmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol (2013), 10: 585–595
Blotière P, Weill A, Ricordeau P, et al. Perforations and haemorrhages after colonoscopy in 2010: a study based on comprehensive French health insurance data (SNIIRAM). Clin Res Hepatol Gastroenterol (2014), 38: 112–117
Soubieres A, Poullis A. Emerging biomarkers for the diagnosis and monitoring of inflammatory bowel disease. // Inflamm Bowel Dis (2016), 22: 2016–2022
Ford A, Bernstein C, Khan K, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis // Am J Gastroenterol (2011), 106(4):590-9
Lamb C, Kennedy N, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults // Gut (2019),68 (Suppl 3):s1-s106
Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment // J Crohns Colitis (2020), 14 (1): 4-22
Feuerstein J, Isaacs K, Schneider Y, et al, for the AGA Institute Clinical Guidelines Committee // AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology (2020), 158(5): 1450-61
Harris S, Wichary J, Zasnik M, Reinish W. Competition in clinical trials in inflammatory bowel disease // Gastroenterology (2019), 157: 1457-1461
https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and
https://news.bms.com/news/corporate-financial/2020/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Pivotal-Phase-3-True-North-Trial-Evaluating-Zeposia-ozanimod-in-Patients-with-Moderate-to-Severe-Ulcerative-Colitis/default.aspx
D’Haens G, Slatkin N, Israel R, Heimanson Z. P097 favorable safety profile for amiselimod, a selective S1P receptor modulator, in Crohn’s disease // Inflammatory Bowel Diseases (2020), 26 (Suppl 1): S1–S2,
https://doi.org/10.1093/ibd/zaa010.002
Sandborn W, Peyrin-Biroulet L, Zhang J, et al. Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis // Gastroenterology (2020), 158: 550-561
Created with Sketch.